Acquisition by Vipin Garg of 18950 shares of Altimmune subject to Rule 16b-3

ALT Stock  USD 5.27  0.07  1.31%   
Slightly above 59% of Altimmune's investor base is looking to short. The analysis of the overall investor sentiment regarding Altimmune suggests that many traders are alarmed. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Altimmune Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Altimmune insider trading alert for acquisition of restricted stock units by Vipin Garg, Director, Officer: President And Ceo, on 23rd of November 2025. This event was filed by Altimmune with SEC on 2025-02-02. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Altimmune's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Altimmune's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Altimmune Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Altimmune Historical Investor Sentiment

Investor biases related to Altimmune's public news can be used to forecast risks associated with an investment in Altimmune. The trend in average sentiment can be used to explain how an investor holding Altimmune can time the market purely based on public headlines and social activities around Altimmune. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Altimmune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Altimmune and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Altimmune news discussions. The higher the estimate score, the more favorable the investor's outlook on Altimmune.

Altimmune Maximum Pain Price Across March 20th 2026 Option Contracts

Altimmune's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Altimmune close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Altimmune's options.

Altimmune Fundamental Analysis

We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Year To Date Return

Year To Date Return Comparative Analysis

Altimmune is currently under evaluation in year to date return category among its peers. Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.

Altimmune Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.

Peers

Altimmune Related Equities

KRROFrequency Therapeutics   4.18   
0%
76.0%
ANROAlto Neuroscience,   3.07   
0%
56.0%
LRMRLarimar Therapeutics   0.75   
0%
13.0%
AURAAura Biosciences   0.46   
0%
8.0%
AMRNAmarin PLC   0.83   
15.0%
0%
ANNXAnnexon   1.39   
25.0%
0%
ACIUAC Immune   2.17   
39.0%
0%
ENGNEnGene Holdings   4.21   
77.0%
0%
LBRXLB Pharmaceuticals   5.44   
99.0%
0%
DBVTDBV Technologies   5.46   
100.0%
0%

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.